Journals / The Anatolian Journal of Cardiology / 2018 / Cilt: 19 - Sayı: 3

Soluble suppression of tumorigenicity-2 for risk stratification in outpatients with heart failure ( Author`s Reply )

Pages
228–229
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗

Özet

-

🔖

Cite This Article

GÜL, İ., YÜCEL, O., ZARARSIZ, A., DEMİRPENÇE, Ö., YÜCEL, H., ZORLU, A., YILMAZ, M. B. (2018). Soluble suppression of tumorigenicity-2 for risk stratification in outpatients with heart failure ( Author`s Reply ). The Anatolian Journal of Cardiology, Cilt: 19 - Sayı: 3, 228–229. https://ajindex.com/articles/365252

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Liu CL, Xue ZQ, Gao SP, Chen C, Chen XH, Pan M, et al. The Relationship between Interleukin-6 Promotor Polymorphisms and Slow Coronary Flow Phenomenon. Clin Lab 2016; 62: 947-53.
  2. Yucel O, Gul I, Zararsiz A, Demirpence O, Yucel H, Cinar Z, et al. Association of soluble ST2 with functional capacity in outpatients with heart failure. Herz 2017 Jun 26. doi: 10.1007/s00059-017-4590-1. [Epub ahead of print] [CrossRef] Mueller T, Jaffe AS. Soluble ST2--analytical considerations. Am J Cardiol 2015; 115(7 Suppl): 8B-21B. [CrossRef] Gül İ, Yücel O, Zararsız A, Demirpençe Ö, Yücel H, Zorlu A, et al. Prognostic role of soluble suppression of tumorigenicity-2 on cardiovascular mortality in outpatients with heart failure. Anatol J Cardiol 2017; 18: 200-5. [CrossRef]